Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 19/20 | 0.70 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 16/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316918 | 0.98 | CALCRL (0.67) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13713338 | 0.96 | CALCRL (0.67) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL14374449 | 0.96 | CALCRL (0.67) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331853 | 0.96 | CALCRL (0.67) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL3314409 | 0.95 | CALCRL (0.78) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331689 | 0.94 | CALCRL (0.62) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331855 | 0.94 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13713011 | 0.94 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13713258 | 0.94 | CALCRL (0.65) | CALCRLRAMP1CYP3A4 | |
| SCHEMBL13331682 | 0.94 | CALCRL (0.61) | CALCRLRAMP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | claimed |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | claimed |
| EP-1558600-B1 | SELECTED CGRP ANTAGONISTS, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-05-07 | — | — | EP | claimed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | claimed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | claimed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2010-05-06 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595312-B2 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | disclosed |
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | RUDOLF KLAUS | 2008-07-24 | — | — | US | disclosed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | disclosed |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | RUDOLF KLAUS | 2008-05-01 | — | — | US | disclosed |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO., KG (DE) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176836-A1 | benzodiazepines; 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-{(R)-1-(4-amino-3-chloro-5-ethyl-benzyl)-2-[4-(4-methyl-piperazin-1-yl)-piperidin-1-yl]-2-oxo-ethyl}-amide; | GABRA1, GABRA5, GABRA2 | CALCRL 160/4885RAMP1 307/4885CYP3A4 444/4885 |
| US-20080103134-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885RAMP1 288/4885CYP3A4 3006/4885 |
| US-20100113411-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 84/4885CYP3A4 1238/4885 |
| US-20060079504-A1 | Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | CALCRL 1/4885RAMP1 84/4885CYP3A4 1238/4885 |
| US-20060142274-A1 | Use of selected CGRP antagonists for combating menopausal hot flushes | BDKRB2, CALCR, GRPR | CALCRL 4/4885RAMP1 202/4885CYP3A4 2927/4885 |
| US-20060142273-A1 | Use of selected CGRP-antagonists in combination with other antimigraine drugs for the treatment of migraine | SCN3A, HTR3A, BDKRB2 | CALCRL 39/4885RAMP1 288/4885CYP3A4 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.